Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ARG1 | P05089 | 1/20 | 0.30 |
| ▸ | ARG2 | P78540 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9962281 | 0.83 | DPP4 (0.48) | POLBALDH1A1MAPTPTGS1DPP4 | |
| SCHEMBL4956469 | 0.83 | DPP4 (0.48) | POLBALDH1A1MAPTPTGS1DPP4 | |
| SCHEMBL19964616 | 0.79 | POLB (0.34) | POLBALDH1A1MAPTPTGS1DPP4 | |
| SCHEMBL3416457 | 0.78 | SPHK1 (0.41) | SPHK1ALDH1A1MAPTPTGS1DPP4 | |
| SCHEMBL3258317 | 0.77 | POLB (0.39) | POLBALDH1A1MAPTPTGS1DPP4 | |
| SCHEMBL12234218 | 0.75 | DPP4 (0.43) | POLBALDH1A1MAPTPTGS1DPP4 | |
| SCHEMBL13164141 | 0.75 | DPP4 (0.43) | POLBALDH1A1MAPTPTGS1DPP4 | |
| SCHEMBL24543407 | 0.75 | DPP4 (0.43) | POLBALDH1A1MAPTPTGS1DPP4 | |
| SCHEMBL21661368 | 0.74 | DPP4 (0.46) | SPHK1POLBALDH1A1MAPTPTGS1 | |
| SCHEMBL8473624 | 0.73 | POLB (0.37) | POLBALDH1A1MAPTPTGS1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220194939-A1 | Novel compounds and methods of use treating fructose-related disorders or diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194939-A1 | Novel compounds and methods of use treating fructose-related disorders or diseases | GCK, KHK, HK1 | SPHK1 71/4885POLB 3687/4885ALDH1A1 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.